Results 211 to 220 of about 24,701 (248)

Depot-medroxyprogesterone acetate: an update

Archives of Gynecology and Obstetrics, 2008
Depo-Provera is a contraceptive approved by the US Food and Drug Administration (FDA) since 1992 and used worldwide by more than 90 million women.Despite the fact that progestins are endogenous hormones that are secreted by the body, its excess might lead to detrimental health effects.
Sayed, Bakry, Zaher O, Merhi, Trudy J, Scalise, Mohamad S, Mahmoud, Ahmed, Fadiel, Frederick, Naftolin   +5 more
openaire   +2 more sources

A radioimmunoassay for serum medroxyprogesterone acetate

Journal of Steroid Biochemistry, 1978
Abstract A radioimmunoassay for measuring medroxyprogesterone acetate in serum or plasma is described using an antiserum produced against the steroid-3-carboxymethyloxime coupled to bovine serum albumin. The method has adequate accuracy, precision and sensitivity and the reliability criteria of the method are compared with those of other ...
K, Shrimanker, B N, Saxena, K, Fotherby
openaire   +2 more sources

Medroxyprogesterone Acetate (Depo-Provera)

Pediatrics, 1980
Members of the American Academy of Pediatrics have asked the Committee on Drugs to comment on the efficacy and the indications for use of the injectable progestin, medroxyprogesterone acetate (Depo-Provera), in adolescents. The Committee has reviewed the available data about the drug and assembled several possible indications for its use in adolescents.
Sydney Segal, Walter R. Anyan, Sanford N. Cohen, John Freeman, Reba M. Hill, Ralph E. Kauffman, Howard C. Mofenson, Albert W. Pruitt, Henry R. Shinefield   +8 more
openaire   +1 more source

Medroxyprogesterone Acetate and Sleep Apnea

Psychiatry and Clinical Neurosciences, 1987
Abstract: Seven patients with sleep apnea DOES and one with sleep apnea DIMS were treated with medroxyprogesterone acetate (MPA). The therapeutic effect was confirmed in most of them by polysomnographic recording. A marked increase of TST was observed in two patients whose AI and/or %SAT remarkably decreased.
openaire   +2 more sources

Toxicology of depot medroxyprogesterone acetate

Contraception, 1994
Depo-Provera (depot-medroxyprogesterone acetate or DMPA), administered either subcutaneously or intramuscularly, has undergone a thorough toxicological evaluation in a number of animal species. DMPA has been tested in short- and long-term toxicity studies in rodents, rabbits, and monkeys.
openaire   +2 more sources

Pharmacist-administered depot medroxyprogesterone acetate

Contraception, 2006
Continuation rates for women using depot medroxyprogesterone acetate (DMPA) for contraception in the United States are very low. Compliance/continuation rates at 3 months range from 57% to 71% with usual care and follow-up. At 6 months the range decreases to between 35% and 63%. The continuation rate at 1 year ranges from 23% to 45%.
openaire   +2 more sources

Glucocorticoid properties of medroxyprogesterone acetate

Life Sciences, 1972
Abstract In healthy young men, the maximum eosinopenic response to 40 mg oral medroxyprogesterone acetate (MPA) was about the same as to 20 mg oral hydrocortisone, though the rates of response were different. The hyperglycemic response to the MPA was also about the same as to the hydrocortisone, though the fasting glucose concentration rose faster ...
Michael Briggs, Maxine Briggs
openaire   +1 more source

CONTRACEPTIVE AND ENDOMETRIAL EFFECTS OF MEDROXYPROGESTERONE ACETATE

Obstetrical & Gynecological Survey, 1969
Present means of contraception are not satisfactory for all women. This study reports on the contraception efficacy and menstrual abnormalities of medroxyprogesterone acetate (Depo-Provera), which was given in an intramuscular dose of 150 mg. every 3 months for 1 year.
openaire   +2 more sources

Medroxyprogesterone Acetate and Diabetes Mellitus

Annals of Internal Medicine, 1976
Excerpt To the editor: Sutton and associates (1) observed one patient with a family history of diabetes mellitus who developed irreversible insulin-dependent diabetes after 1 year of, therapy with ...
JOSEPH C. BOTTINO, CHARLES K. TASHIMA
openaire   +1 more source

Medroxyprogesterone Acetate in Cancer Cachexia

2007
For a long time the use of testosterone-derivative drugs (nandrolone decanoate and others) has been indicated for patients with cancer anorexiacachexia syndrome (CACS) on the basis of a truly protein anabolic effect [1], but the above drugs have a limited use because of some severe sideeffects (liver damage, endocrine effects).
Giorgio Lelli, Benedetta Urbini, Daniela Scapoli, Germana Gilli   +3 more
openaire   +1 more source